HC Wainwright Rates Galectin Therapeutics (GALT) buy
Analyst Matthew Keller maintained a buy rating and an $11 price target on Galectin Therapeutics Inc. as shares change hands around $4.14, a 165.69% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
HC Wainwright rated Galectin Therapeutics Inc. ($GALT) "buy" with a $11 price target on June 23, 2026.
Since the rating, $GALT is up 48.7% after 1 week, up 10.6% after 1 month and up 16.0% to date (from the $3.12 close on Jun 23, 2026).
GALT
Galectin Therapeutics Inc.
Key Points
- HC Wainwright analyst Matthew Keller reiterated a buy rating on Galectin Therapeutics Inc. on June 23, 2026, keeping an $11 price target.
- HC Wainwright's $11 price target implies 165.69% upside from Galectin Therapeutics Inc.'s ($GALT) current $4.14 share price.
- Galectin Therapeutics Inc. shares recently traded at $4.14, giving the biotechnology firm a market value of about $399.4 million.
- Recent regulatory filings show insider activity on June 26, 2026, including open market purchases by Chief Medical Officer Khurram Jamil and insider Harold Shlevin.
Get $GALT trade alerts by text
We text you when insiders, Congress or big funds trade $GALT. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Galectin Therapeutics Inc. alert may contain errors. Disclosures
Analysts Set New Price Targets
HC Wainwright & Co. analyst Matthew Keller kept a positive stance on Galectin Therapeutics Inc. (NasdaqCM: GALT), reiterating a buy rating and an $11 price target on June 23, 2026. With the shares recently changing hands at $4.14, that target implies a sizable runway between the current market price and the firm's goal. The biotechnology firm has caught steady attention from research houses tracking the sector, with HC Wainwright continuing its pattern of bullish outlooks across several small-cap names.
HC Wainwright & Co. vs. the S&P 500
Hypothetical returns from HC Wainwright & Co.'s disclosed trades, not real profit or advice. How we model this.
Galectin Therapeutics Stock Trades Near Moving Averages
Shares of Galectin Therapeutics recently traded at $4.14, staying comfortably above their 200-day moving average of $3.36 and higher than the 50-day moving average of $3.77. The equity moves within a 52-week range spanning a low of $2.03 and a high of $7.13. The company carries a market capitalisation of roughly $399.4 million and a beta of 0.39, reflecting lower volatility than the broader market.
$GALT price target
Galectin Therapeutics Inc. daily closes and this analyst's $11 target. Not advice.
Recent Insider Transactions at Galectin Therapeutics
Recent regulatory filings show multiple insider transactions on June 26, 2026. Chief Medical Officer Khurram Jamil acquired 4,570 shares at an average price of $2.37 per share for a total value of $10,813.99, alongside a separate disposition of 2,533 shares. In addition, insider Harold Shlevin picked up 7,732 shares on the same date at an average price of $1.23 per share amounting to a total value of $9,510.36.
Research Coverage from HC Wainwright
HC Wainwright maintains an optimistic view on several development-stage health care equities alongside its stance on Galectin Therapeutics. The firm keeps an active research desk covering various clinical-stage biopharma companies. Matthew Keller's reiterated rating on Galectin Therapeutics keeps the $11 price target steady from previous coverage, matching the high end of analyst expectations for the firm.
Inside the Clinical Pipeline
Galectin Therapeutics operates out of Norcross, Georgia, focusing on drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin, which is currently undergoing clinical study for patients with advanced liver disease. With nine employees guiding its research efforts, the firm works to advance its pipeline while managing its capital position. The company's next corporate earnings report is slated for August 11, 2025, providing further insight into its financial runway.
What to Watch Next for Galectin Therapeutics
Market participants will monitor upcoming clinical updates from the company's drug candidate pipeline and any further insider filing disclosures. Because analyst ratings and 13F filings look backward or reflect current sentiment without guaranteeing future price action, investors typically weigh these updates alongside broader sector trends and upcoming financial results.
Related Filing Alerts
Source: HC Wainwright's rating change on $GALT (Jun 23, 2026). Written by software, not financial advice. How we make alerts